Actelion downgraded by Merrill Lynch to sell

Actelion was downgraded by Merrill Lynch analyst Erica Whittaker to sell from neutral, asserting the market is overly optimistic about prospects for its Tracleer pulmonary hypertension drug. Merrill estimates fair value for Actelion stock is CHF 136 per share, significantly below the current market. Actelion shares Tuesday were down CHF 3.80, or 2.57%, at CHF 144.20 on volume of 85,957 shares versus the three-month running average of 73,772.2 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.